Sustained virologic response to the HCV in patients with HCV and HIV coinfection is associated with a lowered risk of diabetes and mortality.
Whole grains and possibly cereal fiber, bran appear linked to lower risk for hepatocellular carcinoma.
A team of investigators sought to identify the independent effects of hyperlipidemia and statin exposure on mortality, hepatic decompensation, and hepatocellular carcinoma in individuals with cirrhosis.
Universal healthcare screening at the first clinical encounter of pregnancy was found to be cost-effective and improved health outcomes in women diagnosed with HCV and identification of HCV exposure in neonates.
Topline data from the Phase 3 STELLAR-4 trial showed that selonsertib, an investigational treatment for patients with compensated cirrhosis due to nonalcoholic steatohepatitis (NASH), was not associated with a significant improvement in fibrosis without worsening of NASH.
The ACIP and CDC have approved and released 2019 recommendations for the adult immunization schedule in the US.
Women less likely to be treated than men; treatment visit, medication tied to improved 1-year outcomes.
Increased-risk donors significantly more likely to have positive HBV, HCV screening results.
Physical activity was found to be associated with a reduced risk for hepatocellular carcinoma.
Much of the increase due to decrease in hepatitis C virus infection as indication for transplant.
Worker at Bauer’s Candies facility in Kentucky tested positive for hepatitis A.
Evidence convincing that universal prenatal screening reduces perinatal transmission of HBV.
More incident cases identified in intervention arm with nurse-led primary care-based liver clinics.
Investigators sought to determine the association between liver fibrosis and hepatitis B virus genotype G in patients with comorbid HIV and HBV.
The Advisory Committee on Immunization Practices Hepatitis Vaccines Work Group has updated recommendations for hepatitis A vaccination for PEP and PrEP.
Those with HCV genotype 1 with recent injection drug use and/or current opioid substitution therapy, paritaprevir/ritonavir, ombitasvir, and dasabuvir with/without ribavirin is effective.
Second study shows no significant difference in patients’ survival based on donor BMI.
Patients with chronic HCV undergoing short-term glecaprevir and pibrentasvir treatment show improved cardiovascular and metabolic extrahepatic manifestations.
Findings based on birth cohort, risk-based testing vs opt-out testing in prison system.
The Company has completed a first in human study in healthy volunteers; a Phase 2 trial in adults with NASH is due to begin soon in the US.